EA201390771A1 - Способ получения фармацевтических промежуточных соединений высокой чистоты - Google Patents

Способ получения фармацевтических промежуточных соединений высокой чистоты

Info

Publication number
EA201390771A1
EA201390771A1 EA201390771A EA201390771A EA201390771A1 EA 201390771 A1 EA201390771 A1 EA 201390771A1 EA 201390771 A EA201390771 A EA 201390771A EA 201390771 A EA201390771 A EA 201390771A EA 201390771 A1 EA201390771 A1 EA 201390771A1
Authority
EA
Eurasian Patent Office
Prior art keywords
high purity
intermediate compounds
pharmaceutical intermediate
obtaining pharmaceutical
preparation
Prior art date
Application number
EA201390771A
Other languages
English (en)
Other versions
EA029079B1 (ru
Inventor
Дьёрдь Кованьине Лакс
Дьюла Шимиг
Балаж Волк
Ференц Лорант Барта
Дьёрдь Краснаи
Дьёрдь Ружич
Эва Шипош
Кальман Надь
Дьёрдь Моровьян
Йожеф Баркоци
Адриенн Кестейи
Янош Имре
Габор Бадьински
Original Assignee
Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг filed Critical Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг
Publication of EA201390771A1 publication Critical patent/EA201390771A1/ru
Publication of EA029079B1 publication Critical patent/EA029079B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к промежуточным соединениям, полезным при получении фармацевтически приемлемых солей (+)-7-[4-(4-фторфенил)-6-изопропил-2-(метансульфонилметиламино)пиримидин-5-ил]-(3R,5S)-дигидрокси-гепт-6-еновой кислоты, и к полиморфам указанных промежуточных соединений, к способам их получения и к их применению.
EA201390771A 2010-11-29 2011-11-29 Способ получения фармацевтических промежуточных соединений высокой чистоты EA029079B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000637A HU230987B1 (hu) 2010-11-29 2010-11-29 Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
PCT/HU2011/000113 WO2012073055A1 (en) 2010-11-29 2011-11-29 Method for the preparation of high-purity pharmaceutical intermediates

Publications (2)

Publication Number Publication Date
EA201390771A1 true EA201390771A1 (ru) 2013-11-29
EA029079B1 EA029079B1 (ru) 2018-02-28

Family

ID=89990088

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390771A EA029079B1 (ru) 2010-11-29 2011-11-29 Способ получения фармацевтических промежуточных соединений высокой чистоты

Country Status (15)

Country Link
US (1) US9133132B2 (ru)
EP (1) EP2646420A1 (ru)
JP (1) JP2013543884A (ru)
CN (1) CN103298793B (ru)
AU (1) AU2011334661A1 (ru)
BR (1) BR112013013169A2 (ru)
CA (1) CA2818314A1 (ru)
EA (1) EA029079B1 (ru)
HU (1) HU230987B1 (ru)
IL (1) IL226301A0 (ru)
MX (1) MX2013005961A (ru)
NZ (1) NZ610765A (ru)
UA (1) UA112423C2 (ru)
WO (1) WO2012073055A1 (ru)
ZA (1) ZA201303467B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN103709107B (zh) * 2012-09-29 2016-04-20 安徽省庆云医药化工有限公司 瑞舒伐他汀甲酯的新晶型及其制备方法
CN103848790B (zh) * 2012-12-05 2016-08-03 安徽省庆云医药化工有限公司 瑞舒伐他汀酯的晶型及其制备方法
CN106531756B (zh) * 2016-10-28 2018-05-18 中国计量科学研究院 探测器阳极装置
CN110483412B (zh) * 2019-09-17 2020-06-26 安徽省庆云医药股份有限公司 一种瑞舒伐他汀叔丁酯的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
EA200401533A1 (ru) 2002-05-21 2005-06-30 Ранбакси Лабораторис Лимитед Способ получения росувастатина
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
SI1578733T1 (sl) 2002-12-10 2011-07-29 Ranbaxy Lab Ltd Postopek za pridobitev rosuvastatina
WO2004103977A2 (en) * 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1851206B1 (en) * 2005-02-22 2012-08-15 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
EP1863773A1 (en) 2005-03-22 2007-12-12 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
CN1872841A (zh) * 2005-06-01 2006-12-06 信谊药厂 瑞舒伐他汀钙及其关键中间体的制备方法
US8207333B2 (en) 2005-06-24 2012-06-26 Lek Pharmaceuticals D. D. Process for preparing pure amorphous rosuvastatin calcuim
AU2006261087B2 (en) * 2005-06-24 2010-09-30 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
CZ299215B6 (cs) 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
KR20090113920A (ko) * 2005-10-03 2009-11-02 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 부분입체 이성질체 정제
WO2007099561A1 (en) 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
HU227696B1 (en) 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
WO2008015563A2 (en) * 2006-08-04 2008-02-07 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
WO2008038132A1 (en) * 2006-09-28 2008-04-03 Aurobindo Pharma Limited Crystalline diamine salts of rosuvastatin
HUE028475T2 (en) 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
US20100069635A1 (en) 2006-11-29 2010-03-18 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
US8094450B2 (en) 2007-06-22 2012-01-10 Cole Kepro International, Llc Gaming machine vent cover
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
WO2009118598A1 (en) * 2008-03-24 2009-10-01 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium with high purity
US8653265B2 (en) * 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
EP2387566B1 (en) * 2009-01-14 2014-05-07 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of rosuvastatin
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
US8846915B2 (en) * 2009-08-17 2014-09-30 Aurobindo Pharma Ltd. Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
EP2560970A1 (en) 2010-04-23 2013-02-27 Ranbaxy Laboratories Limited NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts

Also Published As

Publication number Publication date
CA2818314A1 (en) 2012-06-07
WO2012073055A1 (en) 2012-06-07
HU1000637D0 (en) 2011-02-28
CN103298793A (zh) 2013-09-11
US20130338360A1 (en) 2013-12-19
AU2011334661A1 (en) 2013-06-13
HU230987B1 (hu) 2019-08-28
BR112013013169A2 (pt) 2020-10-13
MX2013005961A (es) 2013-07-29
HUP1000637A2 (en) 2012-05-29
ZA201303467B (en) 2014-07-30
EP2646420A1 (en) 2013-10-09
US9133132B2 (en) 2015-09-15
IL226301A0 (en) 2013-07-31
NZ610765A (en) 2015-06-26
JP2013543884A (ja) 2013-12-09
CN103298793B (zh) 2016-06-22
EA029079B1 (ru) 2018-02-28
UA112423C2 (uk) 2016-09-12

Similar Documents

Publication Publication Date Title
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201491671A1 (ru) Гетероциклильные соединения
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
EA201391145A1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
NZ609957A (en) Heterocyclic compounds and uses thereof
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
IN2014MN02598A (ru)
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
EA201390771A1 (ru) Способ получения фармацевтических промежуточных соединений высокой чистоты
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
EA201591195A1 (ru) Новые хинолоновые производные
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
IN2015DN01119A (ru)
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
EA201101655A1 (ru) Производные нитрила, их использование в фармацевтических целях и в композициях
EA201300389A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ KG MD TJ TM